TESARO is a biopharmaceutical company focused on providing therapies to people facing cancer. Co.'s primary focus is to develop treatments for tumors using various approaches, including small molecules and immuno-oncology antibodies, as monotherapies or in combinations. Co.'s products are: ZEJULA® (niraparib), which is for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI® (rolapitant), a neurokinin, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Co. is evaluating its immuno-oncology anti-tumor agents in combination studies with niraparib and other anti-tumor agents. We show 27 historical shares outstanding datapoints in our coverage of TSRO's shares outstanding history.
Understanding the changing numbers of TSRO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TSRO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TSRO by allowing them to research TSRO shares outstanding history
as well as any other stock in our coverage universe. |
Free TSRO Email Alerts:
Video: Shares Outstanding Importance
